CO5721019A2 - Aislados y vacunas antigenicos de virus de bursitis infecciosa - Google Patents

Aislados y vacunas antigenicos de virus de bursitis infecciosa

Info

Publication number
CO5721019A2
CO5721019A2 CO06091380A CO06091380A CO5721019A2 CO 5721019 A2 CO5721019 A2 CO 5721019A2 CO 06091380 A CO06091380 A CO 06091380A CO 06091380 A CO06091380 A CO 06091380A CO 5721019 A2 CO5721019 A2 CO 5721019A2
Authority
CO
Colombia
Prior art keywords
infectious bursitis
bursitis virus
antigenic
isolate
vaccine composition
Prior art date
Application number
CO06091380A
Other languages
English (en)
Inventor
Jeffrey Harold Rodenberg
Mahesh Kumar
Kalen Cookson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5721019(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5721019A2 publication Critical patent/CO5721019A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Una composicion de vacuna que es efectiva para prevenir o mejorar la infeccion por el virus de la Bursitis Infecciosa, que comprende un antigeno o un componente antigénico que tiene las caracteristicas de identificacion sustantivas de un antigeno del virus de la Bursitis Infecciosa como se establece en la figura 1 y se retiene el anticuerpo monoclonal sustancial en cuanto a su reactividad con las variantes tipo Delaware del virus de Bursitis Infecciosa.9.- Una composicion de vacuna contra el virus de la Bursitis Infecciosa, que comprende el aislado antigénico 28-1 del lBDV, y depositado con el ATCC bajo el n·mero de acceso PTA 5848.10.- Un aislado antigénico del virus de la Bursitis Infecciosa que tienen la secuencia de aminoacido establecida en la figura 1 (28-1).11.- Un aislado antigénico del virus de la Bursitis Infecciosa que tiene las caracteristicas de identificacion sustantivas de la cepa depositada con el ATCC bajo el acceso PTA-5848.12.- Un método para inducir la proteccion contra la infeccion del virus de la Bursitis Infecciosa, que comprende administrar a un animal ave una composicion de vacuna que contiene un antigeno que tiene las caracteristicas de identificacion sustantiva de un aislado antigénico de IBDV como se establece en la figura 1.13.- Un método para inducir la proteccion contra la infeccion del virus de la Bursitis Infecciosa, que comprende administrar a un animal ave un aislado antigénico identificado con el ATCC de acceso # PTA-5848.17.- Una composicion de vacuna que comprende un antigeno o un componente antigénico que tiene solamente la sustitucion 318G-D en la region de pico hidrofilico B del VP-2 del virus de la Bursitis Infecciosa, en donde dicha composicion de vacuna es efectiva contra la cepa estandar del lBD y el Grupo 6 y las variantes de la cepa Delaware.18.- Un aislado antigénico del virus de la Bursitis Infecciosa que tiene una sustitucion 318-D en la secuencia de aminoacido VP-2 que es adecuado para uso en una vacuna contra el lBD, dicho aislado retiene la reactividad substancial con una o mas cepas Delaware de IBDV.
CO06091380A 2004-03-12 2006-09-12 Aislados y vacunas antigenicos de virus de bursitis infecciosa CO5721019A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55298904P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
CO5721019A2 true CO5721019A2 (es) 2007-01-31

Family

ID=34994418

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06091380A CO5721019A2 (es) 2004-03-12 2006-09-12 Aislados y vacunas antigenicos de virus de bursitis infecciosa

Country Status (17)

Country Link
US (3) US7338661B2 (es)
EP (2) EP2272949A3 (es)
JP (1) JP4845874B2 (es)
KR (1) KR101172921B1 (es)
CN (1) CN1930284B (es)
AR (1) AR048429A1 (es)
AU (1) AU2005222604B2 (es)
BR (1) BRPI0508660A (es)
CA (1) CA2557844C (es)
CL (1) CL2010001175A1 (es)
CO (1) CO5721019A2 (es)
ES (1) ES2608599T3 (es)
IL (1) IL177903A (es)
MX (1) MXPA06010377A (es)
NZ (1) NZ549687A (es)
WO (1) WO2005089795A2 (es)
ZA (1) ZA200607609B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272949A3 (en) * 2004-03-12 2011-01-19 Wyeth LLC Infectious bursal disease virus antigenic isolates and vaccines
KR101511712B1 (ko) * 2013-04-03 2015-04-13 주식회사 카브 신규 전염성 ｆ낭병 바이러스 ｉｂｄ ｋ7주 및 이를 이용한 전염성 ｆ낭병 백신
MX2018014857A (es) * 2016-06-02 2019-03-07 Zoetis Services Llc Vacuna contra la bronquitis infecciosa.
CN108126191B (zh) * 2016-12-01 2021-04-06 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN108653724B (zh) * 2017-04-01 2020-11-27 普莱柯生物工程股份有限公司 一种用于预防禽减蛋综合征的疫苗组合物、及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US6471962B1 (en) 1987-06-14 2002-10-29 The University Of Maryland Monoclonal antibodies for infectious bursal disease, vaccines and assays for use therewith
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5614409A (en) * 1989-05-30 1997-03-25 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
US5919461A (en) 1989-10-18 1999-07-06 Akzo Nobel N.V. Nonpathogenic infectious bursal disease virus and vaccine
NZ235474A (en) 1989-10-18 1992-12-23 Univ Maryland Virus capable of inducing infectious bursal disease; assay and vaccine
AU7955591A (en) * 1990-05-04 1991-11-27 University Of Maryland At College Park, The Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines
US5595912A (en) * 1990-05-04 1997-01-21 University Of Maryland College Park Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination
IL103939A (en) 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
US5605792A (en) * 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CN1202378A (zh) * 1997-06-02 1998-12-23 财团法人化学及血清疗法研究所 使用细胞系来制备传染性囊病病毒及禽呼肠病毒的方法
US6159472A (en) 1998-11-16 2000-12-12 Akzo Nobel N.V. Intradermal Avian immunization with inactivated vaccines
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
EP1483287A1 (en) * 2002-03-01 2004-12-08 Akzo Nobel N.V. An infectious bursal disease virus variant
PL1908822T3 (pl) * 2003-03-24 2011-03-31 Intervet Int Bv Mutanty wirusa zakaźnego zapalenia torby Fabrycjusza i szczepionki
EP2272949A3 (en) * 2004-03-12 2011-01-19 Wyeth LLC Infectious bursal disease virus antigenic isolates and vaccines

Also Published As

Publication number Publication date
NZ549687A (en) 2008-08-29
JP2007528900A (ja) 2007-10-18
EP2272949A3 (en) 2011-01-19
AR048429A1 (es) 2006-04-26
IL177903A0 (en) 2006-12-31
AU2005222604A1 (en) 2005-09-29
BRPI0508660A (pt) 2007-08-14
ZA200607609B (en) 2008-07-30
ES2608599T3 (es) 2017-04-12
CN1930284B (zh) 2010-06-23
US20080193480A1 (en) 2008-08-14
EP1722814A2 (en) 2006-11-22
WO2005089795A3 (en) 2006-02-23
CA2557844C (en) 2016-06-21
US20050266019A1 (en) 2005-12-01
US8323658B2 (en) 2012-12-04
US7338661B2 (en) 2008-03-04
US20110123560A1 (en) 2011-05-26
AU2005222604B2 (en) 2011-08-11
WO2005089795A2 (en) 2005-09-29
JP4845874B2 (ja) 2011-12-28
KR20060130726A (ko) 2006-12-19
CL2010001175A1 (es) 2011-04-08
CN1930284A (zh) 2007-03-14
KR101172921B1 (ko) 2012-08-13
EP1722814B1 (en) 2016-11-09
IL177903A (en) 2015-04-30
MXPA06010377A (es) 2007-02-14
EP2272949A2 (en) 2011-01-12
CA2557844A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
Chen et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
Hanlon et al. Efficacy of rabies biologics against new lyssaviruses from Eurasia
Meulemans et al. Protective effects of HN and F glycoprotein‐specific monoclonal antibodies on experimental newcastle disease
KR20010089512A (ko) 인플루엔자에 대한 펩티드-기초 백신
Chen et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement
CO5721019A2 (es) Aislados y vacunas antigenicos de virus de bursitis infecciosa
Arous et al. Reduction of Newcastle disease vaccine dose using a novel adjuvant for cellular immune response in poultry
Calvo-Pinilla et al. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
RU2021112503A (ru) Поливалентная вакцина против м. hyo и её применение
RU2011104201A (ru) Вакцины против инфекционного бронхита, полученные из ib-qх-подобных штаммов
KR101442493B1 (ko) 돼지유행성설사병바이러스 약독화주 및 이를 포함하는 돼지유행성 설사병 백신 조성물
CN103341164B (zh) 一种鸡传染性法氏囊病抗原抗体复合物、制剂及制备方法
Lemiere et al. Concomitant Turkey Herpesvirus–Infectious Bursal Disease Vector Vaccine and Oil-Adjuvanted Inactivated Newcastle Disease Vaccine Administration: Consequences for Vaccine Intake and Protection
Geerligs et al. Efficacy, safety, and interactions of a live infectious bursal disease virus vaccine for chickens based on strain IBD V877
US10632189B2 (en) Canine respiratory coronavirus for treatment and protection against bacterial infections
Cook et al. Attenuation of turkey rhinotracheitis virus by alternative passage in embryonated chicken eggs and tracheal organ cultures
Wu et al. Antigenic and immunogenic characterization of infectious bronchitis virus strains isolated in China between 1986 and 1995
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
Isaka et al. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice
Borhani et al. A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies
CN111629751A (zh) 广泛保护性灭活流感病毒疫苗
CN110507819B (zh) 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
Wills et al. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses
Zanella et al. Avian influenza: approaches in the control of disease with inactivated vaccines in oil emulsion
Garcia-Garcia et al. Experimental studies and field trials with recombinant fowlpox vaccine in broilers in Mexico